trial

A Study of Olanzapine in Patients With Acute Agitation

NCTId NCT05803642
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 318 (estimated)
Sponsored by Qilu Pharmaceutical Co., Ltd.
Primary completion 2024-05-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
318 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2023-03-28
Primary completion
2024-05-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineHaloperidol
Indications
Acute Agitation

Sponsors

Qilu Pharmaceutical Co., Ltd.Lead Sponsor

Sites

0 total

Linked catalysts

1
A Study of Olanzapine in Patients With Acute Agitation — primary completion2024-05-07

Facts & assertions

4 sourced
Enrollment
318
Phase
PHASE3
Primary Completion Date
2024-05-07
Status
UNKNOWN
relationships
The graph out of here
drug
Olanzapine
drug
Haloperidol
drug
lead_sponsor
Qilu Pharmaceutical Co., Ltd.
company
indication
Acute Agitation
indication